Jun Bao
Chief Executive Officer bij IMPACT Therapeutics, Inc.
Vermogen: 7 973 $ op 31-03-2024
Profiel
Jun Bao is currently the President & Chief Executive Officer at IMPACT Therapeutics, Inc. and also serves as Chairman at BiTech Pharma, Inc. He previously worked as an Associates Director-Business Development at ICOS Corp., Director-Development & Financial Planning at Onyx Pharmaceuticals, Inc., Director-Worldwide Business Development at Glaxosmithkline China Ltd., Director at Shenogen Pharma Group Ltd., Independent Non-Executive Director at Transcenta Holding Ltd., Finance Manager at Procter & Gamble Co., and Senior Manager-Business Development at CTI BioPharma Corp.
Dr. Bao holds an MBA degree from The University of Chicago, a doctorate degree from the University of Kansas, and an undergraduate degree from Shandong University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 23-08-2023 | 30 000 ( 0.01% ) | 7 973 $ | 31-03-2024 |
Actieve functies van Jun Bao
| Bedrijven | Functie | Begin |
|---|---|---|
BiTech Pharma, Inc.
 BiTech Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services BiTech Pharma, Inc. develops medicines. The private company is based in Emeryville, CA. Xiang Wu Ye has been the CEO of the company since 2008. | Chairman | 03-07-2009 |
IMPACT Therapeutics, Inc.
 IMPACT Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology IMPACT Therapeutics, Inc. manufactures pharmaceutical products. The firm develops discovery and commercialization of novel therapeutics to treat cancer and other life-threatening diseases. The company was founded in 2009 and is headquartered in Nanjing, China. | Chief Executive Officer | 01-09-2018 |
Eerdere bekende functies van Jun Bao
| Bedrijven | Functie | Einde |
|---|---|---|
| TRANSCENTA HOLDING LIMITED | Director/Board Member | 23-08-2023 |
Shenogen Pharma Group Ltd.
 Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Shenogen Pharma Group Ltd. manufactures pharmaceutical products. It develops therapeutics for cancer treatment. The firm’s product pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. The company was founded by Kun Meng, Jing Li, Karen Liu and Zhaoyi Wang in 2006 and is headquartered in Beijing, China. | Director/Board Member | 01-10-2019 |
| Glaxosmithkline China Ltd. | Corporate Officer/Principal | 01-05-2013 |
ICOS Corp.
 ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Corporate Officer/Principal | 01-01-2006 |
| CTI BIOPHARMA CORP. | Corporate Officer/Principal | 01-02-2005 |
Opleiding van Jun Bao
| The University of Chicago | Masters Business Admin |
| University of Kansas | Doctorate Degree |
| Shandong University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| TRANSCENTA HOLDING LIMITED | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
BiTech Pharma, Inc.
BiTech Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services BiTech Pharma, Inc. develops medicines. The private company is based in Emeryville, CA. Xiang Wu Ye has been the CEO of the company since 2008. | Commercial Services |
| Glaxosmithkline China Ltd. | |
Shenogen Pharma Group Ltd.
Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Shenogen Pharma Group Ltd. manufactures pharmaceutical products. It develops therapeutics for cancer treatment. The firm’s product pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. The company was founded by Kun Meng, Jing Li, Karen Liu and Zhaoyi Wang in 2006 and is headquartered in Beijing, China. | Health Technology |
IMPACT Therapeutics, Inc.
IMPACT Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology IMPACT Therapeutics, Inc. manufactures pharmaceutical products. The firm develops discovery and commercialization of novel therapeutics to treat cancer and other life-threatening diseases. The company was founded in 2009 and is headquartered in Nanjing, China. | Health Technology |
